Global Markets for Vaccine Technologies
Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017 at a compound annual growth rate (CAGR) of 5.3%.
- An overview of the global market for human and animal (veterinary) vaccines and related vaccine technologies.
- Analyses of global market trends, with data from 2010, 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017.
- Examination of current and future strategies within the human and animal (veterinary) vaccines markets, including attenuated (live) vaccines, inactivated (killed) vaccines, conjugate vaccines, recombinant/recombinant DNA (rDNA) vaccines, subunit vaccines, toxoid vaccines, and combination vaccines.
- A breakdown of the seven major categories of vaccines broken down by market shares belonging to leading manufacturers and/or suppliers.
- Discussion of human and animal (veterinary) vaccines as to their prophylactic or therapeutic use, with emphasis in the meningococcal/pneumococcal vaccines, influenza vaccines, pediatric vaccines, adult/adolescent vaccines, and travel vaccines.
SCOPE OF THE STUDY
The report studies the various factors impacting the global market for human and animal vaccines. BCC conducted a market evaluation for vaccine types/categories for humans and animals, including their respective regional sales, applications, regulatory aspects, market forecasts, prospects, innovation and challenges, patent analyses, clinical trials, market leaders and market shares of vaccine sales.
The data gathered is for the global markets and statistically validated for the current and forecasted values. Similar techniques were applied for regional data measurements and sales in the respective regions studied. Product details and scientific techniques/platforms are provided based on their commercial and industrial viability.
The emerging markets for orphan drugs include India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.
- Global Markets for CT Scanners (HLC024B)
- Technologies for Long-term Care and Home Healthcare: Global Markets (HLC079D)
- Renal Dialysis Equipment: Technologies and Global Markets (HLC164B)
- Fluoroscopy and C-arms: Technologies and Global Markets (HLC148B)
- Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging (PHM043G)
Global sales of human and animal vaccines reached approximately $25.2 billion in 2009. The market is expected to rise at a compound annual growth rate (CAGR) of 17.9% to reach $64.2 billion by 2015.
- The global market for vaccines is expected to reach $22.4 billion by the end of 2008. It should reach $36.3 billion by 2013, a com¬pound annual growth rate (CAGR) of nearly 11%.
- Although pediatric vaccines traditionally have had the largest share of the market, adult and therapeutic vaccines will likely usurp this position in the near future.
- Patent activity has heightened to an almost frenzied level over the study period, with as many as 250 each year for 2006 and 2007.
- The total worldwide market for prophylactic and therapeutic vaccines is estimated to be $5.8 billion in 2001.
- Growing at an average annual rate (AAGR) of 11.6%, this market is expected to approach $10 billion in 2006.
- Pediatric prophylactic vaccines make up 58% of the current market, but will show the slowest growth, at an AAGR of 8.7% through 2006.
- Adult prophylactic vaccines are the second largest group with sales of nearly $2.4 billion in 2001 and are expected to rise at an AAGR of 10.1% to more than $3.8 billion in 2006.
- Therapeutic vaccines will feature growth of more than 100% on average per year through the period, but by 2006 will still make up only 10.5% of the market.